

Precision Medicine in Oncology Care

Using Every Available Tool CME

FRIDAY, 19 OCTOBER, 2018

PRESENTATION: 18:00 – 20:00

VENUE: MESSE MUNICH, MUNICH, GERMANY | ROOM: HALL B3 – ROOM 22



Medscape
LIVE!

CHAIR

Alexander E. Drilon, MD
Assistant Attending Physician
of Oncology
Memorial Sloan Kettering
Cancer Center
New York, New York
United States

FACULTY

Ulrik Lassen, MD, PhD
Head of Department
Department of Oncology
Copenhagen University
Hospital
Rigshospitalet, Copenhagen

Myung-Jo Ahn, MD, PhD
Professor, Department of
Hematology & Oncology
Samsung Medical Center
Seoul, South Korea

ACTIVITY OVERVIEW

Precision medicine is continuing to evolve as understanding of biomarkers and oncogenic drivers grows and new targeted therapies become available. Data regarding NTRK fusions in a number of different solid tumors, such as lung cancer and sarcoma, and the development of TRK inhibitors illustrate the rapid growth in this field and have important implications for the application of precision medicine. This symposium will provide in-depth coverage of when and how to test patients for NTRK fusions and how to identify patients who may benefit from TRK inhibitor therapy.

TARGET AUDIENCE

This activity is intended for Oncologists, Pathologists, and Pulmonologists.

GOAL STATEMENT

The goal of this activity is to improve understanding of the implications that NTRK fusions have for precision medicine in oncology and to increase knowledge of testing for NTRK fusions and the potential role of TRK inhibitor therapy.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding
 - Who to test for NTRK fusions
 - Clinical trial data on the use of TRK inhibitors in patients whose cancer contains a NTRK fusion
- Have greater competence related to
 - Strategies for optimizing testing for NTRK fusions and obtaining the results in a timely manner
 - Identifying when a patient may benefit from use of TRK inhibitors (ie, patients whose cancer contains a NTRK fusion)

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape



JOINTLY ACCREDITED PROVIDER[™]
INTERPROFESSIONAL CONTINUING EDUCATION

AGENDA

18:00

Presentation

Introduction

Alexander Drilon

NTRK fusions in clinical practice: another tool for precision medicine

Alexander Drilon

18:20

Evolving paradigms with TRK inhibitors

- **Breast cancer**
- **Gastrointestinal cancers**
- **Head and neck cancers (thyroid, salivary gland, etc)**
- **Lung cancer**
- **Sarcoma**
- **Pediatric oncology**

All faculty

19:30

Clinical pearls: What might a diagnostics and treatment algorithm look like?

Alexander Drilon

19:45

Q & A

All faculty